- Home
- AKBA vs OPFI Comparison
AKBA vs OPFI Comparison
Compare AKBA & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- OPFI
- Stock Information
- Founded
- AKBA 2007
- OPFI 2009
- Country
- AKBA United States
- OPFI United States
- Employees
- AKBA N/A
- OPFI N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- OPFI Finance: Consumer Services
- Sector
- AKBA Health Care
- OPFI Finance
- Exchange
- AKBA Nasdaq
- OPFI Nasdaq
- Market Cap
- AKBA 336.2M
- OPFI 290.9M
- IPO Year
- AKBA 2014
- OPFI N/A
- Fundamental
- Price
- AKBA $1.80
- OPFI $11.30
- Analyst Decision
- AKBA Strong Buy
- OPFI Buy
- Analyst Count
- AKBA 1
- OPFI 2
- Target Price
- AKBA $7.50
- OPFI $7.50
- AVG Volume (30 Days)
- AKBA 1.8M
- OPFI 2.6M
- Earning Date
- AKBA 03-13-2025
- OPFI 03-05-2025
- Dividend Yield
- AKBA N/A
- OPFI 1.06%
- EPS Growth
- AKBA N/A
- OPFI 775.86
- EPS
- AKBA N/A
- OPFI 0.38
- Revenue
- AKBA $169,879,000.00
- OPFI $260,661,000.00
- Revenue This Year
- AKBA N/A
- OPFI N/A
- Revenue Next Year
- AKBA $19.31
- OPFI $6.51
- P/E Ratio
- AKBA N/A
- OPFI $29.86
- Revenue Growth
- AKBA N/A
- OPFI 23.85
- 52 Week Low
- AKBA $0.80
- OPFI $2.35
- 52 Week High
- AKBA $2.48
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- AKBA 28.80
- OPFI 41.42
- Support Level
- AKBA $2.07
- OPFI $11.16
- Resistance Level
- AKBA $2.17
- OPFI $15.30
- Average True Range (ATR)
- AKBA 0.08
- OPFI 1.38
- MACD
- AKBA -0.05
- OPFI -0.66
- Stochastic Oscillator
- AKBA 4.60
- OPFI 2.13
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.